Valeant Pharmaceuticals International Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other May 7 Calls Today's Calls

Call Details Valeant Pharmaceuticals International Earnings Conference Call (Q1 2008) Wed, May 7, 2008, 10:00 am Eastern Listen to the archived event audio About Valeant Pharmaceuticals International (NYSE:VRX) Other Calls  Valeant Pharmaceuticals International, a specialty pharmaceutical company, engages in the development, manufacture, and marketing of a range of pharmaceutical products. It primarily offers prescription pharmaceutical products in the areas of neurology, dermatology, and infectious diseases. The company’s neurology products include Diastat and Diastat AcuDial, Mestinon, Cesamet, Librax, Dalmane/Dalmadorm, Migranal, Tasmar, Melleril, and Zelapar. Its dermatology products comprise Efudex/Efudix, Kinerase, Oxsoralen-Ultra, and Dermatix. The company also offers various infectious disease products, such as Virazole, the brand name for ribavirin; and other therapeutic products, including Bedoyecta, Solcoseryl, Bisocard, M.V.I., Nyal, Espaven, and Protamin. In addition, Valeant Pharmaceuticals provides products in the areas of neuromuscular disorders, cancer, cardiovascular disease, diabetes, and psychiatric disorders. As of December 31, 2007, its product portfolio comprised approximately 352 branded products, with approximately 1,974 stock keeping units. The company markets its pharmaceutical products to physicians, hospitals, pharmacies, and wholesalers through its sales force, as well as through wholesalers in the United States, Mexico, Poland, Canada, and Germany. Valeant Pharmaceuticals was founded in 1960 and is headquartered in Aliso Viejo, California. More Info: Quote | Chart | News | Profile | Reports | Research | Msgs | Insider | Financials | Analyst Ratings